Microneedle-mediated Intratumoral Delivery of Anti-CTLA-4 Promotes cDC1-dependent Eradication of Oral Squamous Cell Carcinoma with Limited irAEs

Microneedle-mediated Intratumoral Delivery of Anti-CTLA-4 Promotes cDC1-dependent Eradication of Oral Squamous Cell Carcinoma with Limited irAEs

Head and neck squamous cell carcinoma (HNSCC) ranks sixth in cancer incidence worldwide and has a 5-year survival rate of only 63%. Immunotherapies-principally immune checkpoint inhibitors (ICI), such as anti-PD-1 and anti-CTLA-4 antibodies that restore endogenous antitumor T-cell immunity-offer the...

Full description

Bibliographic Details
Main Authors: Gilardi, M. (Author), Gutkind, J.S (Author), Hollern, D.P (Author), Kupor, D. (Author), Lopez-Ramirez, M.A (Author), Miki, H. (Author), Mikulski, Z. (Author), Proietto, M. (Author), Ramms, D.J (Author), Rueda, R. (Author), Saddawi-Konefka, R. (Author), Sharabi, A. (Author), Soto, F. (Author), Wang, J. (Author), Wang, Z. (Author), Wu, V.H (Author)
Format: Article
Language:English
Published: American Association for Cancer Research Inc. 2022
Subjects:
adverse event
animal
Animals
Carcinoma, Squamous Cell
Head and Neck Neoplasms
head and neck tumor
human
Humans
immunotherapy
Immunotherapy
Mice
mouse
Mouth Neoplasms
mouth tumor
squamous cell carcinoma
Squamous Cell Carcinoma of Head and Neck
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items